1. Useful Clinical Criteria for Identifying Neonates with Congenital Cytomegalovirus Infection at Birth in the Context of an Expanded Targeted Screening Program.
- Author
-
Poletti de Chaurand V, Scandella G, Zicoia M, Arienti F, Fernicola F, Lanteri L, Guglielmi D, Carli A, Vasarri MV, Iozzi L, Cavallero A, Malandrin SMI, Locatelli A, Ventura ML, Sinelli M, and Ornaghi S
- Subjects
- Humans, Infant, Newborn, Female, Pregnancy, Italy epidemiology, Male, Hearing Loss, Sensorineural virology, Hearing Loss, Sensorineural diagnosis, Prevalence, Cytomegalovirus Infections congenital, Cytomegalovirus Infections diagnosis, Neonatal Screening methods, Cytomegalovirus genetics, Cytomegalovirus isolation & purification, Pregnancy Complications, Infectious diagnosis, Pregnancy Complications, Infectious virology
- Abstract
Cytomegalovirus (CMV) is the leading infectious cause of brain defects and neurological dysfunctions, including sensorineural hearing loss (SNHL). Targeted screening in neonates failing the hearing screen is currently recommended in Italy according to national guidelines. However, SNHL may not be present at birth; also, congenital CMV (cCMV) may manifest with subtle signs other than SNHL. Therefore, the inclusion of additional criteria for cCMV screening appears clinically valuable. Starting January 2021, we have implemented expanded targeted cCMV screening at our center, with testing in case of maternal CMV infection during pregnancy, inadequate antenatal care, maternal HIV infection or immunosuppression, birthweight and/or head circumference < 10th centile, failed hearing screen, and prematurity. During the first three years of use of this program (2021-2023), 940 (12.3%) of 7651 live-born infants were tested. The most common indication was birthweight < 10th centile (n = 633, 67.3%). Eleven neonates were diagnosed as congenitally infected, for a prevalence of 1.17% (95%CI 0.48-1.86) on tested neonates and of 0.14% (95%CI 0.06-0.23) on live-born infants. None of the cCMV-infected newborns had a failed hearing screen as a testing indication. Implementation of an expanded cCMV screening program appears feasible and of clinical value.
- Published
- 2024
- Full Text
- View/download PDF